Edition:
United Kingdom

Caroline Humer

CVS to increase genetic testing for some cancer patients

13 Dec 2019

(This December 12 story corrects to Missouri from Montana in last paragraph)

CVS to increase genetic testing for some Aetna cancer patients

12 Dec 2019

NEW YORK, Dec 12 CVS Health Corp said on Thursday it will make it easier for patients with advanced cancer enrolled in some Aetna insurance plans to receive broad genetic gene sequencing tests that can help identify the best drug or treatment for them.

UPDATE 4-CVS quarterly profit beats expectations; shares rise as it eyes growth

06 Nov 2019

Nov 6 CVS Health Corp reported higher-than-expected third-quarter profit on Wednesday as medical costs in its Aetna health insurance business came in below forecasts, and the company said its new strategy of using in-pharmacy clinics would contain healthcare spending going forward.

UPDATE 3-Health insurer Anthem signals better-than-feared 2020 earnings, shares rise

23 Oct 2019

Oct 23 Anthem Inc on Wednesday signaled earnings for 2020 could be better than feared, allaying some concerns that rising medical costs are eating into profits and sending shares of the No. 2 health insurer up 4%.

UnitedHealth sees 2020 profit above Street target; shares climb 8%

15 Oct 2019

UnitedHealth Group Inc on Tuesday provided an optimistic outlook for 2020 profit, saying it expected growth to be at least 13%, which outpaces current Wall Street estimates and sent its shares up as much as 8.6%.

Humira, Rituxan top list of U.S. drugs with biggest price increases: report

08 Oct 2019

NEW YORK AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.

REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report

08 Oct 2019

NEW YORK, Oct 8 AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.

RPT-FOCUS-CVS drug coverage plan based on outside pricing review is off to a slow start

04 Oct 2019

NEW YORK, Oct 3 A CVS Health Corp health plan that uses an outside drug pricing group to help it decide whether to cover certain new medicines has gained little traction with customers, according to its top medical executive, and has drawn fierce criticism from patient advocacy groups.

CVS drug coverage plan based on outside pricing review is off to a slow start

04 Oct 2019

NEW YORK A CVS Health Corp health plan that uses an outside drug pricing group to help it decide whether to cover certain new medicines has gained little traction with customers, according to its top medical executive, and has drawn fierce criticism from patient advocacy groups.

World News